Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.
about
Accelerating the development of a group A Streptococcus vaccine: an urgent public health needStrategies in the development of vaccines to prevent infections with group A streptococcusCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusAntibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroadsM proteins of group A streptococci.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Purification and serological characterization of a type-specific antigen of Streptococcus equisimilisActive and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Homologous and heterologous protection of mice with group A streptococcal M protein vaccines.Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever.Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein.Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin AInfluence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease ModelsDifferences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?Development of Group A streptococcal vaccines: an unmet global health need.Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.Streptococcal rheumatic carditis.Immunization with Streptococcal Heme Binding Protein (Shp) Protects Mice Against Group A Streptococcus Infection.
P2860
Q26739210-D561B7A3-28B5-42B9-97CE-B229C4FB0D59Q26863366-9123C3EF-D658-4C7C-9549-7A22DD6498D6Q27009175-3643E940-7286-4CDE-8F03-03ABCFB7CBBAQ30397437-9FD0FE93-49ED-4165-AC9E-FDEA63BB1999Q33916408-AE9624A5-67CE-40CB-B733-AACD3BD78599Q34067666-DCC6FC77-0612-4A14-BC80-E570807E6332Q34112608-C2789A46-61D2-41D4-8C4B-B466BC551012Q34128905-3E241717-1A10-4BF8-B698-61362E86DB2FQ34194488-C078065A-019D-4E9E-8951-529FA884260BQ34215028-B7A235B3-DAE2-43DE-95C1-68E8DF30CE34Q34413457-18B1318E-5770-44E8-B62D-671376D8230CQ34422357-9C9CBE61-3F47-4C93-819E-6752532B9A5FQ36337367-C4439377-38CE-4F29-AE24-D340458436E1Q36342872-0CAC1834-289B-49B9-8A32-6A222891802EQ36357627-F93BF9B0-900A-4C4C-A312-221F78C52FF7Q37000013-2CDEC2E6-3F7F-41AF-99E8-59A94A7888EBQ37027300-5D005E52-89E5-488A-8F33-F211B4BA6E2AQ37631055-0B723AEF-3A7C-430A-8FE8-7CFFDC8D0AE1Q38631048-86D58E96-CFBB-4F42-B764-04F31F3B2D86Q38897169-D38CA28E-F6C2-417E-9B9B-BFD8944DF03CQ40149945-9B56E5AC-1F8E-4A00-8B88-94BC38B9C92CQ40335751-66D011DC-17E6-4107-9F24-46DF1613E6F4
P2860
Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.
description
1973 nî lūn-bûn
@nan
1973 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1973 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1973年の論文
@ja
1973年論文
@yue
1973年論文
@zh-hant
1973年論文
@zh-hk
1973年論文
@zh-mo
1973年論文
@zh-tw
1973年论文
@wuu
name
Protective study with a group ...... challenge of human volunteers.
@ast
Protective study with a group ...... challenge of human volunteers.
@en
Protective study with a group ...... challenge of human volunteers.
@nl
type
label
Protective study with a group ...... challenge of human volunteers.
@ast
Protective study with a group ...... challenge of human volunteers.
@en
Protective study with a group ...... challenge of human volunteers.
@nl
prefLabel
Protective study with a group ...... challenge of human volunteers.
@ast
Protective study with a group ...... challenge of human volunteers.
@en
Protective study with a group ...... challenge of human volunteers.
@nl
P2093
P2860
P356
P1476
Protective study with a group ...... challenge of human volunteers.
@en
P2093
P2860
P304
P356
10.1172/JCI107372
P407
P577
1973-08-01T00:00:00Z